naltrexone and liraglutide

naltrexone has been researched along with liraglutide in 26 studies

Research

Studies (26)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's19 (73.08)24.3611
2020's7 (26.92)2.80

Authors

AuthorsStudies
Carter, R; Mouralidarane, A; Oben, J; Ray, S; Soeda, J1
Nakazato, M; Ueno, H1
Aldhoon-Hainerová, I; Hainer, V1
Hainer, V1
Aronne, LJ1
Fujioka, K1
Howland, RH1
Bragg, R; Crannage, E1
Megyeri, J; Nuffer, W; Trujillo, JM1
Camilleri, M; Chandar, AK; Dulai, PS; Khera, R; Loomba, R; Murad, MH; Prokop, LJ; Singh, S; Wang, Z1
Braverman-Panza, J; Fujioka, K1
Aronne, LJ; Igel, LI; Kumar, RB; Saunders, KH1
Curry, SA1
Golden, A1
Bersoux, S; Byun, TH; Chaliki, SS; Poole, KG1
Nadolsky, KZ1
Wilding, JPH1
Barrea, L; Cataldi, M; Colao, A; Guida, B; Muscogiuri, G; Savastano, S; Taglialatela, M1
Chatzis, P; Dinas, K; Makris, V; Pratilas, GC; Sotiriadis, A; Tziomalos, K1
Capasso, A; De Biasio, V; Di Munzio, W; Foggia, G; Milano, W1
Barrea, L; Colao, A; Laudisio, D; Muscogiuri, G; Pugliese, G; Savastano, S1
Brown, SA; Izzy, M; Watt, KD1
Lee, SY; Tak, YJ1
Abawi, O; van den Akker, ELT; van der Valk, ES; van der Voorn, B; van Rossum, EFC; Welling, MS1
Hill, A; Levi, J; Venter, F; Wang, J1
Argyrakopoulou, G; Bontozoglou, N; Kalra, B; Kokkinos, A; Konstantinidou, SK; Kouvari, M; Kumar, A; Kumar, M; Kyriakopoulou, K; Mantzoros, CS; Simati, S; Stefanakis, K1

Reviews

18 review(s) available for naltrexone and liraglutide

ArticleYear
Recent advancements in drug treatment of obesity.
    Clinical medicine (London, England), 2012, Volume: 12, Issue:5

    Topics: Anti-Obesity Agents; Benzazepines; Benzoxazines; Bupropion; Clinical Trials as Topic; Drug Combinations; Fructose; Glucagon-Like Peptide 1; Humans; Lactones; Life Style; Liraglutide; Naltrexone; Obesity; Orlistat; Phentermine; Topiramate; Weight Loss

2012
[Cutting-edge of medicine; the prospects of novel anti-obesity drugs].
    Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 2014, Mar-10, Volume: 103, Issue:3

    Topics: Anti-Obesity Agents; Appetite; Appetite Depressants; Benzazepines; Benzoxazines; Bupropion; Clinical Trials as Topic; Drug Approval; Drug Combinations; Drug Discovery; Energy Metabolism; Enzyme Inhibitors; Fructose; Glucagon-Like Peptide 1; Humans; Hypothalamus; Lactones; Lipase; Liraglutide; Metabolic Syndrome; Naltrexone; Obesity; Orlistat; Phentermine; Topiramate

2014
Tolerability and safety of the new anti-obesity medications.
    Drug safety, 2014, Volume: 37, Issue:9

    Topics: Anti-Obesity Agents; Benzazepines; Benzoxazines; Bupropion; Chemistry, Pharmaceutical; Drug-Related Side Effects and Adverse Reactions; Fructose; Glucagon-Like Peptide 1; Humans; Liraglutide; Naltrexone; Obesity; Phentermine; Topiramate

2014
Overview of new antiobesity drugs.
    Expert opinion on pharmacotherapy, 2014, Volume: 15, Issue:14

    Topics: Anti-Obesity Agents; Benzazepines; Benzoxazines; Bupropion; Drug Combinations; Fructose; Glucagon-Like Peptide 1; Humans; Liraglutide; Naltrexone; Obesity; Phentermine; Topiramate; Weight Loss

2014
Evolving directions in obesity management.
    The Journal of family practice, 2014, Volume: 63, Issue:7 Suppl

    Topics: Anti-Obesity Agents; Bupropion; Dopamine Uptake Inhibitors; Forecasting; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Incretins; Liraglutide; Naltrexone; Narcotic Antagonists; Obesity; Receptors, Glucagon

2014
Safety and tolerability of medications approved for chronic weight management.
    Obesity (Silver Spring, Md.), 2015, Volume: 23 Suppl 1

    Topics: Anti-Obesity Agents; Benzazepines; Bupropion; Delayed-Action Preparations; Drug-Related Side Effects and Adverse Reactions; Drugs, Investigational; Fructose; Glucagon-Like Peptide 1; Humans; Liraglutide; Naltrexone; Obesity; Phentermine; Topiramate; United States; United States Food and Drug Administration; Weight Loss

2015
Melatonin, Liraglutide, and Naltrexone/Bupropion for the Treatment of Obesity and Medication-Related Weight Gain.
    Journal of psychosocial nursing and mental health services, 2015, Volume: 53, Issue:6

    Topics: Anti-Obesity Agents; Bupropion; Drug Combinations; Humans; Liraglutide; Melatonin; Naltrexone; Obesity; Psychotropic Drugs; Weight Gain

2015
A Comparison of New Pharmacological Agents for the Treatment of Obesity.
    The Annals of pharmacotherapy, 2016, Volume: 50, Issue:5

    Topics: Anti-Obesity Agents; Benzazepines; Bupropion; Clinical Trials, Phase III as Topic; Drug Combinations; Fructose; Humans; Liraglutide; Naltrexone; Obesity; Phentermine; Topiramate; Weight Loss

2016
Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events: A Systematic Review and Meta-analysis.
    JAMA, 2016, Jun-14, Volume: 315, Issue:22

    Topics: Anti-Obesity Agents; Bayes Theorem; Benzazepines; Drug Combinations; Female; Fructose; Humans; Lactones; Liraglutide; Male; Middle Aged; Naltrexone; Obesity; Orlistat; Phentermine; Randomized Controlled Trials as Topic; Topiramate; Weight Loss

2016
Practical Use of Pharmacotherapy for Obesity.
    Gastroenterology, 2017, Volume: 152, Issue:7

    Topics: Androgens; Anti-Obesity Agents; Antidepressive Agents; Antihypertensive Agents; Antipsychotic Agents; Appetite Depressants; Benzazepines; Bupropion; Drug Combinations; Fructose; Humans; Hypoglycemic Agents; Hypogonadism; Lactones; Liraglutide; Naltrexone; Obesity; Orlistat; Phentermine; Testosterone; Topiramate; Weight Gain

2017
Current pharmacotherapies for obesity: A practical perspective.
    Journal of the American Association of Nurse Practitioners, 2017, Volume: 29, Issue:S1

    Topics: Adult; Anti-Obesity Agents; Benzazepines; Female; Humans; Lactones; Liraglutide; Middle Aged; Naltrexone; Obesity; Orlistat; Phentermine; Risk Reduction Behavior; United States

2017
Pharmacotherapy for obesity: What you need to know.
    Cleveland Clinic journal of medicine, 2017, Volume: 84, Issue:12

    Topics: Adult; Anti-Obesity Agents; Appetite Depressants; Benzazepines; Bupropion; Drug Combinations; Humans; Lactones; Liraglutide; Naltrexone; Obesity; Orlistat; Phentermine

2017
Gender-related issues in the pharmacology of new anti-obesity drugs.
    Obesity reviews : an official journal of the International Association for the Study of Obesity, 2019, Volume: 20, Issue:3

    Topics: Anti-Obesity Agents; Benzazepines; Bupropion; Dose-Response Relationship, Drug; Drug Combinations; Female; Humans; Liraglutide; Male; Naltrexone; Obesity; Patient Selection; Sex Factors; Topiramate; Treatment Outcome; Weight Loss

2019
The Role of Antiobesity Agents in the Management of Polycystic Ovary Syndrome.
    Folia medica, 2018, Dec-01, Volume: 60, Issue:4

    Topics: Androgens; Anti-Obesity Agents; Bupropion; Drug Combinations; Female; Humans; Insulin Resistance; Liraglutide; Naltrexone; Obesity; Orlistat; Polycystic Ovary Syndrome; Weight Loss

2018
Obesity: The New Global Epidemic Pharmacological Treatment, Opportunities and Limits for Personalized Therapy.
    Endocrine, metabolic & immune disorders drug targets, 2020, Volume: 20, Issue:8

    Topics: Anti-Obesity Agents; Bupropion; Epidemics; Global Health; Humans; Liraglutide; Naltrexone; Obesity; Orlistat; Precision Medicine; Weight Loss

2020
New-generation anti-obesity drugs: naltrexone/bupropion and liraglutide. An update for endocrinologists and nutritionists.
    Minerva endocrinologica, 2020, Volume: 45, Issue:2

    Topics: Anti-Obesity Agents; Bupropion; Drug Combinations; Endocrinology; Humans; Liraglutide; Naltrexone; Nutritional Sciences; Obesity

2020
Pharmacotherapy for Weight Loss in Cirrhosis and Liver Transplantation: Translating the Data and Underused Potential.
    Hepatology (Baltimore, Md.), 2021, Volume: 73, Issue:5

    Topics: Anti-Obesity Agents; Bupropion; Drug Therapy, Combination; Humans; Liraglutide; Liver Cirrhosis; Liver Transplantation; Naltrexone; Obesity; Orlistat; Phentermine; Topiramate; Translational Science, Biomedical

2021
Long-Term Efficacy and Safety of Anti-Obesity Treatment: Where Do We Stand?
    Current obesity reports, 2021, Volume: 10, Issue:1

    Topics: Animals; Anti-Obesity Agents; Benzazepines; Bupropion; Humans; Liraglutide; Naltrexone; Obesity; Orlistat; Overweight; Phentermine; Topiramate; United States; United States Food and Drug Administration; Weight Loss

2021

Other Studies

8 other study(ies) available for naltrexone and liraglutide

ArticleYear
Review of pharmacotherapy options for the management of obesity.
    Journal of the American Association of Nurse Practitioners, 2016, Volume: 28, Issue:2

    Topics: Benzazepines; Bupropion; Disease Management; Fructose; Humans; Lactones; Liraglutide; Naltrexone; Obesity; Orlistat; Phentermine; Topiramate; United States

2016
Answers to Clinical Questions in the Primary Care Management of People with Obesity: Pharmacologic Management.
    The Journal of family practice, 2016, Volume: 65, Issue:7 Suppl

    Topics: Anti-Obesity Agents; Benzazepines; Body Mass Index; Bupropion; Guidelines as Topic; Humans; Lactones; Life Style; Liraglutide; Naltrexone; Obesity; Orlistat; Overweight; Phentermine; Primary Health Care; Risk Factors; Treatment Outcome; Weight Loss

2016
Obesity Epidemic: Pharmaceutical Weight Loss.
    Rhode Island medical journal (2013), 2017, Mar-01, Volume: 100, Issue:2

    Topics: Anti-Obesity Agents; Benzazepines; Body Mass Index; Bupropion; Drug Combinations; Fructose; Humans; Lactones; Liraglutide; Naltrexone; Obesity; Orlistat; Phentermine; Weight Loss

2017
Rationale for Utilization of Obesity Pharmacotherapy in the Active Duty Population.
    Military medicine, 2018, 03-01, Volume: 183, Issue:3-4

    Topics: Alcohol Deterrents; Appetite Depressants; Benzazepines; Cohort Studies; Drug Therapy; Humans; Incretins; Liraglutide; Military Personnel; Naltrexone; Obesity; Phentermine; Retrospective Studies

2018
Beyond lifestyle interventions: exploring the potential of anti-obesity medications in the UK.
    Clinical obesity, 2018, Volume: 8, Issue:3

    Topics: Anti-Obesity Agents; Bariatric Surgery; Body Weight Maintenance; Bupropion; Health Services; Humans; Life Style; Liraglutide; Naltrexone; Obesity; Primary Health Care; Specialization; State Medicine; United Kingdom; Weight Loss; Weight Reduction Programs

2018
[Pharmacotherapy for obesity].
    Nederlands tijdschrift voor geneeskunde, 2021, 01-19, Volume: 165

    Topics: Anti-Obesity Agents; Bariatric Surgery; Bupropion; Combined Modality Therapy; Drug Combinations; Drug Therapy, Combination; Humans; Hunger; Life Style; Liraglutide; Naltrexone; Obesity; Satiation; Treatment Outcome; Weight Loss

2021
Estimated minimum prices and lowest available national prices for antiobesity medications: Improving affordability and access to treatment.
    Obesity (Silver Spring, Md.), 2023, Volume: 31, Issue:5

    Topics: Anti-Obesity Agents; Bupropion; Drug Combinations; Health Care Costs; Health Services Accessibility; Liraglutide; Naltrexone; Orlistat; Phentermine; Topiramate

2023
Circulating levels of proglucagon-derived peptides are differentially regulated by the glucagon-like peptide-1 agonist liraglutide and the centrally acting naltrexone/bupropion and can predict future weight loss and metabolic improvements: A 6-month long
    Diabetes, obesity & metabolism, 2023, Volume: 25, Issue:9

    Topics: Bupropion; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide 2; Glucagon-Like Peptides; Humans; Liraglutide; Naltrexone; Obesity; Overweight; Peptides; Proglucagon; Weight Loss

2023